seekingalpha.com/pr/...rth-quarter-full-year-financial-results
About:
www.caladrius.com/product-candidates/clbs12/
|
CLBS03 fällt in Phase 2 Diabetis Studie durch
www.caladrius.com/press-release/...ent-onset-type-1-diabetes/
seekingalpha.com/news/...23-percent-disappointing-clbs03-data
www.caladrius.com/press-release/...ear-end-financial-results/
Caladrius Zahlen für Q1/19
www.caladrius.com/press-release/...provides-corporate-update/
Zahlen für Q3/19
www.caladrius.com/press-release/...provides-corporate-update/
Zahlen für Q1/20
" Based on existing programs and projections, the Company remains confident that its current cash balances will fund its operations into the second half of 2021."
www.caladrius.com/press-release/...quarter-financial-results/
www.caladrius.com/press-release/...-2020-scientific-sessions/
Zahlen für Q3/20
"Secures new capital to support cash runway through the end of 2021"
www.caladrius.com/press-release/...quarter-financial-results/
www.sec.gov/Archives/edgar/data/320017/...oratepresentati.htm
erster Patient in Phase 2b Studie mit CLBS16 behandelt
Dieser Anstieg wundert mich nicht, im Dezember (Posting #13) hatte ich bereits auf die Unterbewertung von Caladrius hingewiesen ("Cash > MK").
seekingalpha.com/news/...e-study-with-clbs16-in-heart-disease
25 Mio. $ Privatplatzierung
www.caladrius.com/press-release/...million-private-placement/
65 Mio. $ Offering
"The Company currently intends to use the net proceeds from the offering for working capital and general corporate purposes, including the advancement of its CD34+ technology"
www.caladrius.com/press-release/...market-under-nasdaq-rules/
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
45 | Caladrius Bioscience zieht an... | Balu4u | Balu4u | 24.11.23 09:03 | ||
2 | Neostem Inc. | iwanooze | iwanooze | 25.04.21 03:24 | ||
13 | A0MY0C | Heron | inso | 03.07.12 17:58 |